ThinkGenetic combines modern machine learning with practical information in genetics to solve a major concern in healthcare – the identification of patients living with undiagnosed rare genetic conditions
Boston, MA, OCT 7, 2021 – ThinkGenetic, Inc. (thinkgenetic.com) is proud to announce the co-winning of this year’s Horizon Prize, powered by MIT Solve, with their solution FindEHR.
Solve, an initiative of the Massachusetts Institute of Technology (MIT), finds incredible tech-based social entrepreneurs all around the world, then brings together their innovation ecosystem and a community of members to fund and support these entrepreneurs to help them drive lasting, transformational impact. The Horizon Prize, sponsored by/enabled by Horizon Therapeutics plc, is a global innovation challenge focused on speeding diagnosis and care for people impacted by rare disease. This year visionaries, academics, and inventors from a pool of more than 138,000 individuals in over 137 countries applied for a winning prize of $150,000 in funding.
“Congratulations to ThinkGenetic on being one of the first recipients of The Horizon Prize,” said Tim Walbert, chairman, president and chief executive officer, Horizon Therapeutics. “Your entrepreneurial approach to leveraging genetic-sequencing data to proactively identify patients at risk for a rare condition has the potential to improve the quality of life for millions of patients and their families. I applaud and respect the drive and passion it takes to bring your idea to fruition. On behalf of rare disease patients around the world, thank you.”
FindEHR, short for “Finding Individuals Needing Diagnosis through Electronic Health Records,” effectively leverages the potential of big data and artificial intelligence to assist healthcare providers in solving their patient’s medical mysteries. Each FindEHR proprietary validated algorithm combs electronic health records and flags at-risk patients for a specific underlying genetic condition. The flagged records are then screened by a genetic counselor. Healthcare providers are notified and receive real-time education about their patient’s symptoms, genetic risk level, referral, free sponsored-testing options, and any FDA approved therapies or clinical trials for the specific genetic condition.
Accepting the award was ThinkGenetic CEO and founder, Dave Jacob, who is also a patient living with a rare genetic condition. “At the highest level, the goal at ThinkGenetic is to help identify individuals at risk of having a genetic condition,” says Jacob. “We are thrilled with this recent win and the company is buzzing with excitement as we enter our Series A funding round. With the funding won from MIT Solve, ThinkGenetic plans to expand its team to cover more conditions and bring FindEHR to even more healthcare systems.”
To stay up to date on the latest business developments of ThinkGenetic and the company’s progress, please visit https://thinkgenetic.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
About ThinkGenetic
ThinkGenetic is digitally revolutionizing undiagnosed patient identification with the goal of shortening the diagnostic journey for those with an underlying genetic condition. Harnessing the power of electronic health data and validated proprietary algorithms, our solutions precisely identify at-risk patients and provide resources to support critical healthcare decisions. For more information, visit thinkgenetic.com.
###
Downloadable Version of Release [PDF]
U.S. Media Contact:
Ruth O’Keefe
Vice President, Marketing and Patient Advocacy
ruth@thinkgenetic.com
